UNIONDALE, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a diversified diagnostics, genomics, and consumer healthcare company, today reported ...
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re ...
Hosted on MSN
ProPhase Labs signals $50M net collection target and strategic initiatives as Crown Medical litigation advances
Ted Karkus, Chairman & CEO, opened by emphasizing the critical importance of shareholder voting on the company's proxy, noting, "If you do not vote for our proxy, you are putting our company in harm's ...
Company Actively Pursuing Strategic Alternatives Including the Potential Sale of Nebula Genomics and DNA Complete to Unlock Immediate Cash GARDEN CITY, NY, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ProPhase ...
ProPhase Labs announces BE-Smart's validation for esophageal disease diagnostics, achieving over 95% success in detecting critical biomarkers. ProPhase Labs Inc. announced the successful validation of ...
Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call ...
An update from Prophase Labs ( (PRPH)) is now available. On December 29, 2025, ProPhase Labs, Inc. disclosed that it had failed to regain compliance with Nasdaq’s $1.00 minimum bid price requirement ...
Hello and good morning, everyone. Welcome to today's presentation. My name is Noella Alexander-Young, Virtual Event Moderator here at Renmark Financial Communications. On behalf of our team we want to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results